




# PHARMACEUTICAL 2020

Neos Therapeutics Inc.  
Rank 265 of 358





## PHARMACEUTICAL 2020

Neos Therapeutics Inc.  
Rank 265 of 358

The relative strengths and weaknesses of Neos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neos Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points. The greatest weakness of Neos Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -29%, being 66% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	66,559
Cost of Goods Sold	25,123
Intangible Assets	12,543
Liabilities, Current	63,355
Liabilities, Non-Current	33,648
Other Assets	4,426
Other Compr. Net Income	1.0
Other Expenses	36,142
Other Liabilities	0
Other Net Income	1,533
Other Revenues	64,649
Property and Equipment	7,345
Research and Development	8,582
Selling, General and Administrative Expense	13,237

Output Variable	Value in 1000 USD
Assets	90,873
Liabilities	97,003
Expenses	83,084
Revenues	64,649
Stockholders Equity	-6,130
Net Income	-16,902
Comprehensive Net Income	-16,902
Economic Capital Ratio	-29%